Security key
60855D408
Moleculin Biotech, Inc. - Common stock, par value $0.001 per share (MBRX)
CUSIP: 60855D408
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common stock, par value $0.001 per share
- Total 13F shares
- 152,127
- Total 13F value
- $347,908
- Share change
- +52,486
- SEC-reported price per share
- $2.29
- Number of holders
- 20
- Value change
- +$62,947
- Number of buys
- 8
- Number of sells
- 5
- Shares outstanding
- 19,517,575
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
20
Top holders
10
MBRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Moleculin Biotech, Inc. SEC filings
Moleculin Biotech, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 60855D408
Recent filing periods:
Ownership snapshot
Top reported holders of MBRX - Moleculin Biotech, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
CITADEL ADVISORS LLC
0.17%
JANE STREET GROUP, LLC
0.12%
VANGUARD GROUP INC
0.08%
GEODE CAPITAL MANAGEMENT, LLC
0.08%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$872,587
1,586,521 shares
|
+$185,087 | 30 Jun 2025 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.17%
|
$109,511
33,085 shares
|
— | 31 Dec 2025 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.12%
|
$74,640
22,550 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
0.08%
|
$51,450
15,544 shares
|
— | 31 Dec 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.08%
|
$50,106
15,138 shares
|
— | 31 Dec 2025 |
| UBS Group AG |
13F
Company
|
0.03%
|
$19,407
5,863 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
20
Shares
152,127
Rows available
20
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
17
Q1 2026 holders
20
Holder diff
3
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend